TY - JOUR
T1 - Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease
AU - Zhao, Shushan
AU - Adebiyi, Morayo G.
AU - Zhang, Yujin
AU - Couturier, Jacob P.
AU - Fan, Xuegong
AU - Zhang, Hongqi
AU - Kellems, Rodney E.
AU - Lewis, Dorothy E.
AU - Xia, Yang
N1 - Funding Information:
This work was supported by U.S. National Institutes of Health, National Heart, Lung, and Blood Institute Grants HL113574, HL114457, HL136969, and HL137990 (to Y.X.). The authors declare no conflicts of interest.
Publisher Copyright:
© FASEB 2018.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/5
Y1 - 2018/5
N2 - Sphingosine-1-phosphate (S1P) is a biolipid involved in chronic inflammation in several inflammatory disorders. Recent studies revealed hat elevatedS1Pcontributes to sickling insickle celldisease (SCD), adevastating hemolytic, genetic disorder associated with severe chronic inflammation and tissue damage. We evaluated the effect of elevated S1P in chronic inflammation and tissue damage in SCD and underlying mechanisms. First, we demonstrated that interfering with S1P receptor signaling by FTY720, a U.S. Food and Drug Administration-approved drug, significantly reduced systemic, local inflammation and tissue damage without antisickling effects. These findings led us to discover that S1P receptor activation leads to substantial elevated local and systemic IL-6 levels in SCD mice. Genetic deletion of IL-6 in SCD mice significantly reduced local and systemic inflammation, tissue damage, and kidney dysfunction. At the cellular level, we determined that elevated IL-6 is a key cytokine functioning downstream of elevated S1P, which contributes to increased S1P receptor 1 (S1pr1) gene expression in the macrophages of several tissues in SCD mice. Mechanistically, we revealedthatS1P-S1PR1 signaling reciprocally up-regulated IL-6 gene expression in primary mouse macrophages in a JAK2-dependent manner. Altogether, we revealedthat elevatedS1P, coupledwithmacrophageS1PR1 reciprocally inducing IL-6 expression, is akey signaling network functioning as a malicious, positive, feed-forward loopto sustain inflammation and promote tissue damage in SCD. Our findings immediately highlight novel therapeutic possibilities.
AB - Sphingosine-1-phosphate (S1P) is a biolipid involved in chronic inflammation in several inflammatory disorders. Recent studies revealed hat elevatedS1Pcontributes to sickling insickle celldisease (SCD), adevastating hemolytic, genetic disorder associated with severe chronic inflammation and tissue damage. We evaluated the effect of elevated S1P in chronic inflammation and tissue damage in SCD and underlying mechanisms. First, we demonstrated that interfering with S1P receptor signaling by FTY720, a U.S. Food and Drug Administration-approved drug, significantly reduced systemic, local inflammation and tissue damage without antisickling effects. These findings led us to discover that S1P receptor activation leads to substantial elevated local and systemic IL-6 levels in SCD mice. Genetic deletion of IL-6 in SCD mice significantly reduced local and systemic inflammation, tissue damage, and kidney dysfunction. At the cellular level, we determined that elevated IL-6 is a key cytokine functioning downstream of elevated S1P, which contributes to increased S1P receptor 1 (S1pr1) gene expression in the macrophages of several tissues in SCD mice. Mechanistically, we revealedthatS1P-S1PR1 signaling reciprocally up-regulated IL-6 gene expression in primary mouse macrophages in a JAK2-dependent manner. Altogether, we revealedthat elevatedS1P, coupledwithmacrophageS1PR1 reciprocally inducing IL-6 expression, is akey signaling network functioning as a malicious, positive, feed-forward loopto sustain inflammation and promote tissue damage in SCD. Our findings immediately highlight novel therapeutic possibilities.
KW - JAK2
KW - Macrophage
KW - S1PR1
UR - http://www.scopus.com/inward/record.url?scp=85048479268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048479268&partnerID=8YFLogxK
U2 - 10.1096/fj.201600788RR
DO - 10.1096/fj.201600788RR
M3 - Article
C2 - 29401601
AN - SCOPUS:85048479268
VL - 32
SP - 2855
EP - 2865
JO - FASEB Journal
JF - FASEB Journal
SN - 1530-6860
IS - 5
ER -